The numbers in this study reinforce my thinking we may be
The numbers in this study reinforce my thinking we may be waiting for 42 day data. For example in this study (tolcilizumab):
SOC at 28 days:
47% leave the hospital
33% die
therefore: 20% unresolved
Treatment at 28 days:
54% leave the hospital
29% die
therefore: 17% unresolved
The number of patients unresolved at 28 days is much larger than the improvement between SOC and treatment. As Dr Javitt noted on the Dr Yo video the 28 day mortality end point is an FDA anachronism and may not be the appropriate target. Thoughts anyone?
3
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
LakeShore Biopharma's Financial Guidance for 2025 LakeShore Biopharma Co., Ltd (NASDAQ: LSB) is a pioneering global biopharmaceutical company focused on the discovery, development, and delivery of new vaccines and therapeutic biologics that target infectious diseases and cancer. The Company has recently provided an overview of its financial expectations for the first half...
Continue Reading
Exciting Drilling Developments at the Gaspé Copper Project Osisko Metals Incorporated (the “Company” or "Osisko Metals") (TSX-V: OM; OTCQX: OMZNF; Frankfurt: 0B51) is thrilled to share their recent drilling outcomes from the 2025 drilling campaign at the Gaspé Copper Project located in Eastern Québec. This project is making waves due to its substantial copper...
Continue Reading
Upcoming Investor Conference Participation by The Honest Company In an exciting announcement from Los Angeles, The Honest Company (NASDAQ: HNST) has declared its participation in an upcoming investor conference, a significant opportunity to connect with investors and share insights on their mission for clean and sustainable personal care products. This event promises to...
Continue Reading
Recent Trends in Used Jet Prices The aviation market is seeing significant changes, particularly in the prices of used jets. Recent reports indicate that the asking prices for these aircraft have been declining steadily, reflecting broader trends in the market. According to the latest analysis, the monthly average prices for pre-owned jets have fallen by around 2.35% in...
Continue Reading
ClearBridge Energy Midstream Opportunity Fund Inc. Financial Report ClearBridge Energy Midstream Opportunity Fund Inc. (NYSE: EMO) has recently shared vital financial metrics showcasing its ongoing asset stability and growth potential. The Fund proudly reported an impressive net asset value as it continues to manage investments strategically amidst dynamic market...
Continue Reading
